# Biomarker-Guided Antidepressant Selection

> **NCT07680140** · PHASE4 · RECRUITING · sponsor: **Weill Medical College of Cornell University** · enrollment: 27 (estimated)

## Conditions studied

- Depression - Major Depressive Disorder
- Treatment-resistant Depression (TRD)
- rTMS
- Ketamine
- fMRI

## Interventions

- **DEVICE:** TMS
- **DRUG:** Ketamine

## Key facts

- **NCT ID:** NCT07680140
- **Lead sponsor:** Weill Medical College of Cornell University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-08-10
- **Primary completion:** 2028-09
- **Final completion:** 2028-12
- **Target enrollment:** 27 (ESTIMATED)
- **Last updated:** 2026-09-23

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07680140

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07680140, "Biomarker-Guided Antidepressant Selection". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07680140. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*